Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2010-2011, in Healthy Subjects Aged Over 6 Months Old to 18 Years Old

PHASE4CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

May 31, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

AdimFlu-S 2010-2011, inactivated

"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL~6 months\~\<3 years;0.25 mL per injection2 injections at 4 weeks apart~3\~\<9 years;0.5 mL per injection2 injections at 4 weeks apart~9\~\<18 years;0.5 mL per injection1 injections"

Sponsors
All Listed Sponsors
lead

Adimmune Corporation

INDUSTRY